Trial · NCT05610189
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
NCT05610189, Phase 1, Completed, Cerevel Therapeutics, LLC
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease. Trials, record NCT05610189. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05610189
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
- NCT number
- NCT05610189
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 25 participants, actual
- Lead sponsor
- Cerevel Therapeutics, LLC
- Conditions
- Parkinson Disease
- Interventions
- Tavapadon
- First posted
- 2022-11-09
- Last updated
- 2024-02-08
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Observed Plasma Concentration (Cmax) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Primary | Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Minimum Steady-state Plasma Concentration (Cmin,ss) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Average Steady-state Plasma Concentration (Cavg,ss) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Trough Concentration (Ctrough) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Time of Maximum Observed Concentration (Tmax) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Degree of Fluctuation [(Cmax - Cmin)/Cavg,ss] of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Peak-to-Trough Ratio (PTR) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Swing [(Cmax - Cmin)/Cmin,ss] of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Apparent Clearance of Tavapadon From Plasma (CL/F) | Pre-dose and at multiple timepoints post-dose up to Day 28 |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05610189
GET https://conductscience.org/api/trials/v1/NCT05610189/registered